Senseonics Reports Strong One-Year Real-World Data for Eversense 365

Core Insights - Senseonics Holdings, Inc. (SENS) presented its first real-world evidence for the Eversense 365 continuous glucose monitoring (CGM) system, demonstrating strong performance over a full year of use [1][4] Company Performance - The Eversense 365 system has shown strong patient adherence with an average transmitter wear time of 93.8% and a Time in Range (TIR) of 66%, indicating effective glycemic control [6][7][8] - The integration of Eversense 365 with automated insulin delivery systems has shown promising early results, with a TIR of 77% in initial users [10] - Senseonics reported a significant increase in total revenues for the third quarter of 2025, rising to $8.1 million from $4.3 million year-over-year, primarily driven by U.S. adoption [12] - The company achieved a gross profit of $3.5 million in the latest quarter, a notable improvement from a gross loss of $4.1 million in the previous year [13] Market Position and Trends - The global blood glucose monitoring devices market is projected to grow from $15.53 billion in 2025 to $30.18 billion by 2033, with a compound annual growth rate (CAGR) of 8.8% from 2026 to 2033, driven by the rising prevalence of diabetes and an aging population [11] - Following the announcement of the real-world evidence, SENS shares increased by 11.8% in a single trading session, although the stock has seen a decline of 27.9% over the past six months [3]